Revenue and net profit declined year-over-year, but operating cash flow improved sharply. The company completed a major acquisition, expanded plasma resources, and advanced innovative drug development, while maintaining a strong balance sheet and robust market position.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.